Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Merrimack Pharmaceuticals announced an annual dividend on Friday, April 7th. Shareholders of record on Wednesday, May 17th will be paid a dividend of $1.06 per share on Friday, May 26th. The ex-dividend date is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released its earnings results on Wednesday, August, 9th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.08. During the same period in the previous year, the company earned ($0.40) EPS. View Merrimack Pharmaceuticals' Earnings History.

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Merrimack Pharmaceuticals.

4 brokerages have issued 1 year price objectives for Merrimack Pharmaceuticals' shares. Their predictions range from $5.00 to $7.00. On average, they anticipate Merrimack Pharmaceuticals' stock price to reach $6.00 in the next year. View Analyst Ratings for Merrimack Pharmaceuticals.

Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Merrimack reported a dismal second quarter with its top and bottom lines missing estimates.With the sale of Onivyde, Merrimack is back to being a development-stage biopharmaceutical company. The successful development of the three lead candidates in its pipeline is critical for Merrimack’s growth. Moreover, two of the candidates, MM-121 and MM-141, are still being evaluated in phase II studies. The third candidate, MM-310 entered phase I study in the first quarter of 2017. Also, shares of the company have underperformed the industry year to date. However, the cash received from Ipsen was used to pay down the huge debt and return value to shareholders in the form of dividends. Moreover, the company has also invested a part of the proceeds to develop its streamlined oncology pipeline." (8/14/2017)
• 2. J P Morgan Chase & Co analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)

Merrimack Pharmaceuticals saw a increase in short interest in July. As of July 31st, there was short interest totalling 25,171,185 shares, an increase of 2.0% from the July 14th total of 25,683,568 shares. Based on an average daily trading volume, of 1,037,040 shares, the days-to-cover ratio is presently 24.3 days. Approximately 20.0% of the company's shares are sold short.

Some companies that are related to Merrimack Pharmaceuticals include Abeona Therapeutics (ABEO), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Novavax (NVAX), Codexis (CDXS), Idera Pharmaceuticals (IDRA), Corvus Pharmaceuticals (CRVS), Horizon Discovery Group PLC (HZD), Curis (CRIS), Advaxis (ADXS), Nabriva Therapeutics AG (NBRV), Voyager Therapeutics (VYGR), Protagonist Therapeutics (PTGX), Arbutus Biopharma Corporation (ABUS), Organovo Holdings (ONVO), NewLink Genetics Corporation (NLNK), Compugen (CGEN) and OncoMed Pharmaceuticals (OMED).

Merrimack Pharmaceuticals' management team includes the folowing people:

• Gary L. Crocker, Chairman of the Board
• Richard Peters M.D., Ph.D., President, Chief Executive Officer, Principal Financial Officer, Director
• John L. Green, Chief Accounting Officer, Controller
• Ellen K. Forest, Head of Human Resources
• Sergio L. Santillana, Chief Medical Officer
• Ulrik B. Nielsen Ph.D., Director
• John M. Dineen, Independent Director
• Vivian S. Lee, Independent Director
• John Mendelsohn M.D., Independent Director
• Michael E. Porter Ph.D., Independent Director

Merrimack Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (13.03%), Vanguard Group Inc. (5.14%), TIAA CREF Investment Management LLC (4.20%), Franklin Resources Inc. (2.99%), State Street Corp (1.69%) and Northern Trust Corp (1.09%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Edward J Stewart, Michael E Porter, Vivian S Lee and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., FMR LLC, Teachers Advisors LLC, TIAA CREF Investment Management LLC, Schwab Charles Investment Management Inc., Cannell Peter B & Co. Inc. and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Airain ltd, Clear Harbor Asset Management LLC, Alliancebernstein L.P., State of Wisconsin Investment Board, Engineers Gate Manager LP, Creative Planning, Stonebridge Capital Management Inc. and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $1.20.